Are pharmacological randomised controlled clinical trials relevant to real-life asthma populations? : A protocol for an UNLOCK study from the IPCRG by Lisspers, Karin et al.
PROTOCOL OPEN
Are pharmacological randomised controlled clinical trials
relevant to real-life asthma populations? A protocol for an
UNLOCK study from the IPCRG
Karin Lisspers1, Pedro Teixeira2, Coert Blom3, Janwillem Kocks4,5, Björn Ställberg1, David Price6 and Niels Chavannes7
npj Primary Care Respiratory Medicine (2016) 26, 16016; doi:10.1038/npjpcrm.2016.16; published online 14 April 2016
INTRODUCTION
Asthma has a high prevalence worldwide with a high incidence in
primary care settings in many countries.1 It is by deﬁnition a
variable disease with a broad spectrum of clinical phenotypes,
in which management and treatment can be difﬁcult.2–8 The aim
of asthma treatment is optimal control of the disease, which
according to Global Initiative for Asthma (GINA) guidelines
implies both symptom control and prevention of exacerbations.1
Despite several treatment options, studies show that about half
of the patients have poor asthma control.2,3 When asthma is
not controlled, it decreases the quality of life, increases the risk
of exacerbations and premature death and is a high cost for
the society.2,3
There are concerns that current asthma treatment is based on
research with subjects who are not representative of the patients
seen in clinical practice.9 Guidelines for the management of
asthma are usually developed on the basis of the available
empirical evidence, and particular emphasis is placed on the
conclusions of randomised controlled clinical trials (RCTs)
and meta-analyses of RCTs that have been placed at the top of
the evidence hierarchy.10 However, most RCTs have restricted
inclusion criteria to obtain a high level of internal validity and
usually recruit patients from secondary health-care settings.
The external validity of RCTs, which provides evidence for
major clinical guidelines, may be questioned if they are not
representative of real-life populations in primary care.11–15 In the
2007 study by Travers et al, only 4% (range 0–36%) of participants
with asthma in a population-based survey met the eligibility
criteria to be included in 17 major RCTs cited in the GINA
guidelines.14 The same study found that only 6% (range 0–43%) of
participants receiving asthma treatment also met the eligibility
criteria. The proportion of patients with asthma from primary care
settings that would be eligible for the major RCTs is unknown.
If the proportion is similar to that found in the study by
Travis et al., then the generalisability of the conclusions and the
clinical relevance of major RCTs may be questionable, and they
have not been improved in the past decade. There is a need to
explore the external validity of pharmacological RCTs in primary
care populations. The UNLOCK (Uncovering and Noting Long-
Term Outcomes in COPD and asthma to enhance knowledge)
project15 of the International Primary Care Respiratory Group
(IPCRG) covers a broad primary care population that may help
clarify the external validity of these RCTs.
AIMS AND OBJECTIVES
The aim of this study is to determine whether the inclusion criteria
for patients with asthma in the major RTCs supporting GINA
guidelines are representative of real-life primary care populations
with asthma. The study will address the following research
questions:
1. What proportion of patients in primary care would be eligible
for the major RCTs assessing patients at treatment step two
heading for step three?
2. What are the clinical characteristics of these patients when
compared with participants in major RCT studies?
DISCUSSION
Asthma is a highly prevalent disease worldwide with variability
and a large range of phenotypes.1–8 The management and
treatment of patients with asthma in primary care is a challenge,
and many patients still suffer from poor asthma control.2 The
major international clinical guidelines for the prevention and
management of asthma are inﬂuenced by the empirical evidence
and conclusions of RCTs.9–14 However, RCTs tend to be highly
selective in terms of inclusion and exclusion criteria for people
with asthma and may under-represent primary care populations
with asthma. Smokers, for example, are usually excluded from
registration RCTs assessing inhaled corticosteroids (ICS), as
smoking is known to reduce the efﬁcacy of ICS.16 Other common
exclusion criteria are pregnancy, lactation, elderly patients and
other chronic diseases such as ischaemic heart disease. A common
inclusion criterion is a bronchodilator FEV1 reversibility of 12 or
15%, which is not a frequent clinical sign in real-life asthma
patients, and in the Travers study, 71 (or 76%) of participants with
asthma were excluded.14
RCTs are important in establishing the efﬁcacy and short-term
safety of new therapies, but there are limitations in evaluation of
effectiveness of the therapies in the real world.17 The assessment
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of the external validity of asthma RCTs is therefore needed to
better understand the clinical relevance of their conclusions. There
should be discussion on the need for effective studies, pragmatic
trials and observational studies, as a complement to RCTs, to
evaluate treatment outcomes in real-life clinical settings including
the whole asthma population. The main weakness of these
studies might be a lower internal validity, which needs to be
addressed in the design of the studies. When developing
guideline recommendations in the future, data from both efﬁcacy
and effectiveness studies should be evaluated with the strengths
and weaknesses given.18
This study will provide estimates of the proportion of real-life
primary care populations that are eligible for RCTs. It will also
present descriptive characteristics of primary care patients
compared with patients included in RCTs. This will present
relevant information for the adequacy and use of GINA and other
major guidelines in primary health-care settings.16–20 Previous
ﬁndings suggest that the level of representation of the population
with asthma14 and chronic obstructive pulmonary disease
(COPD)13 in RCTs may be lower than desirable. This study can
inform not only the development of future clinical practice
guidelines17–20 but also the way asthma clinical trials are being
designed and implemented.10 The study will tell us more about
the patients who are not eligible for these major RCTs, and it may
also provide new insights into why the control of asthma in many
patients does not appear to improve in spite of the implementa-
tion of the treatment strategies that are recommended in
guidelines.
MATERIALS AND METHODS
Study design
The study will use an observational design for comparing baseline
characteristics of asthma patients in primary care databases with
the inclusion criteria in the pharmacological RCTs that support
major international guidelines (i.e., GINA).
Data collection and inclusion criteria
Data collection will involve two steps:
1. Step one will identify the major relevant RCTs used in GINA
guidelines.
2. Step two will identify the primary care data sets that contain
the required variables to assess eligibility for participation in
the major RCTs.
In step one, a Systematic Review focusing the search on selected
asthma international guidelines (i.e., GINA) will be conducted in
order to identify all studies that ﬁt the following criteria:
● Randomised controlled clinical trial
● Pharmacological treatment at GINA management step 2
heading for step 3
● RCT sample size n4400
● Other criteria (e.g., mainly adult population)
The systematic review will follow the PRISMA21 statement
guidelines and follow the steps identiﬁed in Figure 1.
In step two, members of the IPCRG UNLOCK group will be
invited to participate in the study with primary care data sets that
include the variables listed in Table 1.
Participants identiﬁed in the data sets will remain anonymous.
Patient conﬁdentiality will be assured in the collection and
merging of the data sets.
Data analysis
Data will be analysed according the deﬁned criteria for the
identiﬁcation of RCTs. Statistical analysis of the data sets will
provide summary descriptive statistics, means, measures of
dispersion and proportions. The statistical analysis will focus on
group classiﬁcation values, and no individual statistical values will
be computed or revealed.
Ethical approval
All included data sets will require approval by local primary care
research ethics committees.
Figure 1. Flowchart of RCT identiﬁcation process.
Table 1. List of variables for data set inclusion in the study
Variables Required Optional
Age (412 years) √
Gender √
Medication: ICS, LABA, SABA, combination,
Montelukast—(last 3 months) ﬁxed combination
(ICS/LABA)
√
One of:
Asthma control (GINA or ACQ or ACT) √
QoL (miniAQLQ)
Smoking history: (never–former–current) √
Latest lung function assessment
FEV1 % of predicted √
FEV1 reversibilty
FEV1/FVC (VC) ratio
Allergy (pollen, pets, house dust mite) √
Allergic rhinitis √
Comorbidities heart disease (i.e., heart failure or
ischaemic heart disease)
√
Asthma control (i.e., according to GINA: last
week: daytime symptoms, night symptoms
rescue medication and exacerbations history,
courses of oral steroids history or ACQ or ACT)
√
QoL (i.e., miniAQLQ)
Abbreviations: ACQ, asthma control ouestionnaire; ACT, asthma control
test; ICS, inhaled corticosteroids; LABA, long-acting β-agonists; miniAQLQ,
mini quality of life questionnaire; QoL, quality of life; SABA, short-acting
β-agonists.
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